| Dr Wendy R Rogers, PHARMD | |
|
334 Town Center Ave, Big Sky Medical Center Pharmacy, Big Sky, MT 59716 | |
| (406) 995-6500 | |
| Not Available |
| Full Name | Dr Wendy R Rogers |
|---|---|
| Gender | Female |
| Speciality | Pharmacist |
| Location | 334 Town Center Ave, Big Sky, Montana |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1316223308 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 183500000X | Pharmacist | 5083 (Montana) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr Wendy R Rogers, PHARMD Po Box 161529, Big Sky Medical Center Pharmacy, Big Sky, MT 59716-1529 Ph: (406) 995-6500 | Dr Wendy R Rogers, PHARMD 334 Town Center Ave, Big Sky Medical Center Pharmacy, Big Sky, MT 59716 Ph: (406) 995-6500 |
News Archive
A substantial proportion of pharmaceutical industry payments to authors of oncology clinical trials published in major scientific journals are not disclosed, new research shows. The publications focused on clinical trials that tested new cancer drugs.
Elan Corporation, plc today announced that it has enrolled the first patient in a Phase 2 clinical trial of ELND005 (Study AG201) for the treatment of agitation/aggression in patients with moderate to severe Alzheimer's disease (AD).
On January 29, 2010, Sacred Heart Medical Center was cited and fined $8,000 for failing to adhere to state and national H1N1 influenza safety standards. The Department of Labor and Industries Division of Occupational Safety and Health issued the citation and fine for violation of Center for Disease Control and Occupational Safety and Health Administration guidelines on H1N1 and also for violation of the DOSH Directive on Enforcement Procedures for High or Very High Occupational Exposure Risk to the 2009 H1N1 Influenza.
AOL News examines health officials' concerns about the world-wide spread of drug-resistant strains of tuberculosis, focusing on the U.S. and Mexico.
KineMed Inc. today announced the renewal of a non-exclusive research collaboration with Pfizer Inc. for the advancement of novel approaches in metabolic disease, in particular Type II diabetes.
› Verified 8 days ago
Ryan Burfeind, PHARM.D. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 334 Town Center Avenue, Big Sky, MT 59716 Phone: 406-995-6500 Fax: 406-995-6510 |